Hints and tips:
Related Special Reports
...Eli Lilly and Vertex declined to comment on the talks....
...“We’re pleased to work with Lilly to reimagine a pharmacy experience that can support better care outcomes.”...
...“There’s not the clear-cut clinical evidence like physicians wanted, the products don’t stop the disease like the patients wanted, they’re never going to be as big a blockbuster as industry wanted and they...
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...in the fill-finish stage of drugmaking because most manufacturers run their production lines “close to full capacity”, said Gil Roth, president of the Pharma & Biopharma Outsourcing Association global industry...
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
...Eli Lilly has agreed to buy cancer biotech Point Biopharma for about $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price amid a severe cash crunch in the biotech industry....
...According to Dealogic, the outlay by Novo Nordisk and Eli Lilly compares to a total of $305mn that the entire pharmaceutical industry spent on acquisitions and partnerships in the field in the previous ten...
...The recent shift in tone has seen Warren Buffett’s Berkshire Hathaway and drugmaker Eli Lilly overtake Tesla in terms of market capitalisation....
...Some analysts say non-opioid pain medication could be the next blockbuster class of drugs, with an impact on the industry similar to the weight-loss medications....
...Big drugmakers are rushing to develop drugs that could compete in the anti-obesity market dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound....
...In the relatively young US sports betting industry, there is no time for self satisfaction....
...That view was echoed by Tricia Bryan, a WeightWatchers member who has lost 17lbs since pairing the Core programme with a Clinic prescription for Eli Lilly’s Zepbound. “The medication is a tool....
...Novo Nordisk and Eli Lilly have struggled to keep up with soaring demand for obesity treatments....
A glut of apartments available in the French capital this summer is pushing down prices
...But drugs that simultaneously tackle obesity, diabetes and heart disease would be good for public health as well as the pharma industry’s bottom line....
...Lilly has avoided the transformational but risky megamergers that became a feature of the pharmaceutical industry over the past two decades until US regulators started intervening more recently....
An unwinding of the Ticketmaster deal no longer looks far-fetched
...Today, we look at a hot topic rocking the healthcare industry and beyond: obesity drugs....
...The airline industry is largely united in opposition to the rule....
...In February’s mid-stage trials, Eli Lilly’s weight loss drug tirzepatide showed promise against MASH....
...“The industry concentration we are seeing now is all about technology,” Marsh said....
People in the US are being squeezed to such an extent that they are spending less altogether
...The partnership deals follow several others in the industry....
International Edition